IGFBP-AS1: A Potential Drug Target and Biomarker for Insulin-Like Growth Factor-B (IGFBP) Activation

Target Name: IGFBP-AS1

NCBI ID: G101928278

IGFBP-AS1

Other Name(s): IGFBP5 antisense RNA 1, transcript variant X1 | IGFBP-AS1 variant X1 | IGFBP5 antisense RNA 1

IGFBP-AS1: A Potential Drug Target and Biomarker for Insulin-Like Growth Factor-B (IGFBP) Activation

Abstract:

IGFBP-AS1, a novel antisense RNA 1, has been identified as a potential drug target and biomarker for Insulin-Like Growth Factor-B (IGFBP) activation. IGFBP is a family of transmembrane proteins that play a crucial role in cell growth and development, including muscle, bone, and pancreatic growth. Inactivated IGFBP has been linked to various diseases, including obesity, diabetes, and cancer. Therefore, the identification of IGFBP-AS1 as an antisense RNA 1 offers new insights into the regulation of IGFBP function and potential therapeutic interventions.

Introduction:

IGFBP is a family of transmembrane proteins that belong to the insulin-like growth factor (IGF) signaling pathway. IGFBP consists of four isoforms: IGFBP1, IGFBP2, IGFBP3, and IGFBP4. These isoforms differ in their extracellular domain, including the presence or absence of an N-terminal calbindin repeat and a C-terminal basic region. IGFBP functions as a negative regulator of cell growth, displaying a negative correlation with cell proliferation and survival.

IGFBP-AS1: A Unique RNA Interference Target

IGFBP-AS1, also known as IGFBP5 antisense RNA 1, is a novel antisense RNA 1 that has been identified in the IGFBP gene. It is a 24.8-nt RNA molecule, which is predominantly expressed in the brain and pancreatic tissue. IGFBP-AS1 contains a unique stem-loop structure and a specific binding site within the first exon of the IGFBP gene.

IGFBP-AS1 functions as an RNA interferase, specifically, it targets IGFBP-AS1 mRNA for cleavage. IGFBP-AS1 interacts with the IGFBP protein and blocks its function as a negative regulator of cell growth. This interaction between IGFBP-AS1 and IGFBP creates a potential window for therapeutic interventions.

Drug Target Potential:

IGFBP-AS1 has been identified as a potential drug target for treating various diseases associated with IGFBP imbalance, including obesity, diabetes, and cancer. The identification of IGFBP-AS1 as an antisense RNA 1 provides a new mechanism for targeting IGFBP function. IGFBP-AS1 can be used as a target for small molecules, antibodies, or CRISPR/Cas9 genome editing techniques.

Biomarker Potential:

IGFBP-AS1 can also be used as a biomarker for monitoring IGFBP function and its activity in diseases. For instance, IGFBP-AS1 levels can be used as a diagnostic marker for cancer associated with IGFBP imbalance, such as pancreatic cancer. Additionally, IGFBP-AS1 levels can be used as a marker for tracking the efficacy of IGFBP-targeted therapies in diseases associated with IGFBP overactivity, such as obesity and diabetes.

Conclusion:

IGFBP-AS1 is a unique antisense RNA 1 that has been identified in the IGFBP gene. Its unique stem-loop structure and specific binding site within the first exon of the IGFBP gene make it an attractive target for small molecules, antibodies, or CRISPR/Cas9 genome editing techniques. IGFBP-AS1 has been shown to function as an RNA interferase, specifically, it targets IGFBP-AS1 mRNA for cleavage, which creates a potential window for therapeutic interventions. Furthermore, IGFBP-AS1 can be used as a biomarker for monitoring IGFBP function and its activity in diseases, making it an important addition to the growing list of potential drug targets and biomarkers.

Protein Name: IGFBP5 Antisense RNA 1

The "IGFBP-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGFBP-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets